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Abstract High level of serum lactate dehydrogenase (LDH)
is a well-known poor prognostic factor in patients with malig-
nancies. However, there was no data on overall survival (OS)
in cancer patients with serum LDH level > 1000 IU/L, and the
prognostic value of the changes in LDH over time for OS had
not been reported. Clinical data of 311 cancer patients with
metastatic disease with serum LDH >1000 IU/L (four times
upper limit of normal) admitted consecutively to a single cen-
ter were reviewed in this retrospective study. LDH level
ranged from 1002 to 8235 U/L with a mean of 1689 U/L.
The median OS was 1.7 months (95 % CI: 1.4–2.0). About
half of patients (n = 163, 52 %) died within 2 months with the
median OS of 0.5 months (95 % CI: 0.3–0.7). Only 173 pa-
tients were indicated for salvage treatment. Fifty-one patients’
serum LDH level decreased to normal at 2 months following
chemotherapy; OS was significantly longer in these patients
(22.6 months, 95 % CI: 10.9–34.3, p < 0.001) compared to
those with persistently abnormal serum LDH at 2 months
(4.0 months, 95 % CI: 3.4–4.6). The independent factors that
increased the death risk were ECOG performance status 3–4
(HR: 2.05, 95 % CI: 1.42–2.97, p < 0.001), supportive care
only (HR: 2.91, 95 % CI: 2.06–4.10, p < 0.001), and persis-
tently abnormal serum LDH at 2 months (HR: 2.72, 95 % CI:
1.67–4.42, p < 0.001). In conclusion, serum LDH
level > 1000 IU/L predicted a terminal stage in metastatic
cancer patients. OS was significantly prolonged in patients
indicated for effective palliative treatment and LDH level de-
creased to normal at 2 months.
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Introduction
Lactate dehydrogenase (LDH) is a metabolic enzyme widely
expressed in different tissues and is detectable in serum, which
catalyzes the interconversion of pyruvate and lactate during
glycolysis and gluconeogenesis [1]. It has long been known
that many human cancers have higher LDH levels than normal
tissues [1]. Increased LDH may also be a prognostic tumor
marker in many other solid tumors, including colorectal can-
cer [2], nasopharyngeal carcinoma [3, 4], lung cancer [5–7],
breast cancer [8, 9], prostate cancer [10], germ cell cancer [11,
12], and melanoma [13, 14]. The serum level of LDH corre-
lated with tumor burden and was thought to reflect the tumor’s
growth and invasive potential [15]. It has long been appreci-
ated that LDH is a prognostic factor for survival, being one of
the five clinical features known as the international prognostic
index (IPI) for non-Hodgkin’s lymphoma [16] and the
Memorial Sloan-Kettering Cancer Center (MSKCC) risk clas-
sification for metastatic renal cell carcinoma [17].
The determination of remaining life expectancy is of great
importance for patients with advanced cancer, both in guid-
ance of cancer therapies and providing information for
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patients and their relatives. Regardless of primary cancer type,
patients with advanced cancer have much in common, such as
fatigue, pain, and heavy tumor burden. Few studies have eval-
uated the value of LDH >1000 IU/L (four times upper limit of
normal, ULN) as a predictor of survival time in metastatic
cancer patients.
In this retrospective study, overall survival (OS) of cancer
patients with serum LDH greater than 1000 IU/L at baseline
was evaluated. Correlation between better clinical outcomes
and decrease of baseline serum LDH to normal level after




Medical records of all cancer patients with histologically con-
firmed primary and/or metastatic disease (including solid tu-
mors and lymphoma) admitted to the Fudan University
Shanghai Cancer Center (Shanghai, China) consecutively
from January 2005 to May 2015 were reviewed. All patients
whose serum LDH level detected for the first time to be great-
er than 1000 IU/L (4 × ULN) were included into this study.
The exclusion criteria included: incomplete medical history or
suffering from two or multiple primary malignant neoplasm.
Clinical features such as age, ECOG performance status, treat-
ment (chemotherapy or palliative care), and serum LDH
(baseline and post 2-month) were collected. Patients were cat-
egorized into three groups based on serum LDH level at
2 months after baseline: decrease to normal, persistently ab-
normal, and died within 2 months. Written informed consent
was obtained from all patients. The study was approved by the
Institutional Review Board of the Fudan University Shanghai
Cancer Center.
Laboratory measurement of serum LDH
LDHmeasurement was performed locally at our cancer center
using Roche cobas 8000. The normal range is 120–250 U/L.
Once the patients were enrolled, serum LDH was collected at
least every 4 weeks. Serum LDH was detected with the same
machine from 2005 to 2015, and with the same normal range.
Statistical analysis
The primary objectives of this analysis were to determine the
OS for patients with metastatic disease whose LDH >1000 IU/
L and to evaluate whether changes in LDH over time were a
potential prognostic and a predictive biomarker for OS. OS
was defined as the interval between the day when LDH
level > 1000 IU/L was detected at the first time during
admission to this hospital and the date of death or last
follow-up visit if the patients were still alive.
Mean serum level of LDH for each subgroup was com-
pared by standard analysis-of-variance (ANOVA) procedures.
Survival curves were estimated by the Kaplan-Meier method
and analyzed by the log-rank test. Cox regression was used for
univariate and multivariate survival analyses, and a reduced
model was applied using stepwise backward elimination until
only significant (P < 0.05) variables remained in multivariate
survival analysis. A p value of <0.05 was considered statisti-
cally significant. Statistical analyses were performed using the
Statistical Package for the Social Sciences version 12.0.
Results
Patients
A total of 311 patients with serum LDH >1000 IU/L were
enrolled into this study. Patients’ characteristics (as baseline)
were shown in Table 1. The majority of patients (n = 198,
64 %) had ECOG scoring of 3, and seven patients (2 %) had
4. The most commonly seen tumor of origin was gastrointes-
tinal cancer (34 %), followed by lymphoma (n = 57) (18 %),
breast cancer (16 %), lung cancer (14 %), nasopharyngeal
cancer (5 %), and others (13 %). The majority of patients
(n = 254, 82 %) had metastatic solid tumors, except for 57
patients with lymphoma of which 27 patients were diagnosed
with stage II–III. There was a significant difference between
the three LDH groups in the ECOG performance status
(p < 0.001), as well as the administration of treatment
(p < 0.001) (Table 2).
LDH changes over time and outcome
Serum LDH level at baseline ranged from 1002 to 8235 U/L
with a mean of 1689 U/L. About half of the patients (173,
56 %) had anti-tumor therapy while the others received sup-
portive care. LDH >1000 IU/L predicted poor survival with a
median OS of only 1.7 months was observed (95 % CI: 1.4–
2.0, Fig. 1A), with an overall cumulative 1-year survival of
15.6 %.
Among the 311 patients, 163 patients (52 %) died
within 2 months with the median OS of only 0.5 months
(95 % CI: 0.3–0.7). About half of patients (148, 48 %)
lived longer than 2 months and had the information of
LDH after 2-month treatment. All patients were catego-
rized into three groups according to LDH level at
2 months after baseline: decreased to normal, persistent-
ly abnormal, and died within 2 months. The 1-year sur-
vival rate for the three LDH groups was 64.7 %,
14.7 %, and 0.7 %, respectively (p < 0.001). LDH
returned to normal (≤250 IU/L) at 2 months was
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observed in 51 (16 %) patients after chemotherapy with
an OS of 22.6 months (95 % CI: 10.9–34.3), which was
significantly longer than those with persistently abnor-
mal serum LDH level (4.0 months, 95 % CI: 3.4–4.6,
p < 0.001, Fig. 1b).
No positive association between different primary tu-
mor of origin and OS was observed. However, further
analysis of patients with lymphoma showed different OS
for patients at different disease stage. Ten patients of stage
II disease had significantly longer OS (17.7 months, 95 %
CI: 10.7–24.7, p < 0.001) compared with 17 patients with
stage III disease (1.5 months, 95 % CI: 0.1–2.9) and 30
patients with stage IV disease (1.1 months, 95 % CI: 0.7–
1.5).
Univariate and multivariate models of overall survival
There were no significant differences in OS according to
age, gender, and primary tumor site in univariate analyses.
Three variables were found to be associated with a signif-
icant increased in the risk of death, including poor ECOG
scoring of 3–4 (p < 0.001), supportive care without che-
motherapy (p < 0.001), and persistently abnormal serum








Age (years) <65 44 (86.3 %) 85 (87.6 %) 129 (79.1 %) 0.168
≥65 7 (13.7 %) 12 (12.4 %) 34 (20.9 %)
Gender Male 27 (52.9 %) 54 (55.7 %) 93 (57.1 %) 0.873
Female 24 (47.1 %) 43 (44.3 %) 70 (42.9 %)
ECOG 0–2 42 (82.4 %) 57 (58.8 %) 7 (4.3 %) <0.001
3–4 9 (17.6 %) 40 (41.2 %) 156 (95.7 %)
Treatment Chemotherapy 51 (100 %) 82 (84.5 %) 40 (24.5 %) <0.001
Supportive care 0(0.0 %) 15 (15.5 %) 123 (75.5 %)
Primary tumor Gastrointestinal cancer 11 (21.6 %) 34 (35.1 %) 61 (37.4 %) 0.145
Lymphoma 18 (35.3 %) 13 (13.4 %) 26 (16.0 %)
Breast cancer 8 (15.7 %) 18 (18.6 %) 24 (14.7 %)
Lung cancer 7 (13.7 %) 14 (14.4 %) 22 (13.5 %)
Nasopharyngeal cancer 1 (2.0 %) 6 (6.2 %) 8 (4.9 %)
Others 6 (11.8 %) 12 (12.4 %) 22 (13.5 %)
There was a significant difference between the three LDH groups in the ECOG performance status (p< 0.001), as well as administration of treatment
(p < 0.001)
Table 1 Patients’ characteristics at baseline (n = 311)
Features Patients, n (%) Baseline LDH level (U/L) p value
Mean Range
Age (years) <65 258 (83 %) 1706 1002–8235 0.591
≥65 53 (17 %) 1608 1010–6479
Gender Male 174 (56 %) 1713 1004–8235 0.613
Female 137 (44 %) 1659 1002–5953
ECOG 0–2 106 (34 %) 1549 1002–5006 0.058
3–4 205 (66 %) 1758 1002–8235
Treatment Chemotherapy 173 (56 %) 1580 1002–5006 0.052
Supportive care 138 (44 %) 1826 1002–8235
Primary tumor Gastrointestinal cancer 106 (34 %) 1714 1006–7817 0.083
Lymphoma 57 (18 %) 1953 1002–8235
Breast cancer 50 (16 %) 1731 1002–5953
Lung cancer 43 (14 %) 1541 1004–2803
Nasopharyngeal cancer 15 (5 %) 1434 1019–2328
Others 40 (13 %) 1453 1017–3000
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LDH level at 2 months after baseline (p < 0.001).
(Table 3).
These three covariates were also significantly associated
with poor survival after adjustment for all other variables in
the full multivariate model. The independent factors that in-
creased the risk of death were ECOG performance status 3–4
(HR: 2.05, 95 % CI: 1.42–2.97, p < 0.001), supportive care
only (HR: 2.91, 95 % CI: 2.06–4.10, p < 0.001), and persis-
tently abnormal LDH level at 2 months, (HR: 2.72, 95 % CI:
1.67–4.42, p < 0.001). (Table 3).
Discussion
In the present study, the median OS was only 1.7 months for
patients with extremely high level LDH >1000 IU/L. OS was
significantly longer up to 22.6 months in patients who had
tolerated effective salvage treatment and LDH level decrease
to normal at 2 months.
In our daily clinical practice, the majority of patients with
advanced or metastatic disease could be detected to have ex-
tremely high serum level of LDH (greater than 4 × ULN),
Table 3 Univariate and multivariate models for overall survival in patients with initial LDH level > 1000 IU/L
Factor Univariate Multivariate
HR 95 % CI p value HR 95 % CI p value
Age ≥ 65 years old 1.38 0.99–1.92 0.056
Gender: female 0.83 0.65–1.07 0.149
ECOG: 3–4 vs. 0–2 5.46 4.05–7.35 <0.001 2.05 1.42–2.97 <0.001
Treatment: support care vs.
chemotherapy




Lymphoma 0.82 0.57–1.18 0.288
Breast cancer 1.03 0.71–1.49 0.883
Lung cancer 1.23 0.83–1.83 0.308
Others 1.05 0.70–1.58 0.826
Nasopharyngeal cancer 1.57 0.85–2.88 0.148
LDH at 2 months after baseline Decreased to normal 1.00 1.00
Persistently abnormal 3.70 2.31–5.91 <0.001 2.72 1.67–4.42 <0.001
Died within 2 months 22.34 13.80–36.15 <0.001 12.59 7.39–21.43 <0.001
The independent factors that increased the risk of death were ECOG performance status 3-4(HR: 2.05, p<0.001), supportive care only (HR: 2.91,
p<0.001), and persistently abnormal LDH level at two months (HR: 2.72, p<0.001)
Fig. 1 a Kaplan-Meier survival curves of all patients with baseline LDH
>1000 IU/L. The median OS for patients with baseline LDH >1000 IU/L
was only 1.7 months (95 % CI: 1.4–2.0). bKaplan-Meier survival curves
by patients’ LDH level at 2 months after baseline. Median overall
survival, LDH decreased to normal at 2 months group: 22.6 months
(95 % CI: 10.9–34.3); LDH persistently abnormal group: 4.0 months
(95 % CI: 3.4–4.6); and died within 2 months group: 0.5 months (95 %
CI: 0.3–0.7), respectively
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where the oncologists often predicted these patients with a
poor prognosis. Estimation of remaining life expectancy of
patients with metastatic disease is one of the greatest concerns
[18]. But no exact survival data could be given during the
communication between doctors and patients. This study re-
vealed that remaining life expectancy was extremely short for
metastatic cancer patients with LDH greater than 4 × ULN.
Hence, for those patients who could tolerate toxicities of che-
motherapy, effective and sufficient chemotherapy was urgent-
ly needed.
It was reported that high LDH level was associated with
poor therapy response [19]. However, in the present study,
among the 173 patients receiving chemotherapy, 51 had serum
LDH level decrease to normal after 2 months, achieving a
significantly enhanced survival. This is a strong evidence to
support effective chemotherapy of full dose even in patients
with high LDH level.
Notably, the prognostic role of serum LDH in oncology has
long been recognized. LDH is a key enzyme in the process of
energy production in cancer cells, it catalyzes the conversion
of pyruvate to lactate in hypoxic conditions [4]. Since its func-
tion in anaerobic metabolism, cancer cells grow even after
their rapid proliferation that leads to low-oxygen conditions
in the tumor microenvironment [20]. Thus, LDH plays an
important role in tumor progression and maintenance [21,
22]; inhibition of LDH inhibits tumor progression and has
been considered for the therapeutic target of cancer energy
metabolism [21]. LDH levels are increased in response to
tissue injury or during disease states; LDH could be a marker
of tumor burden for advanced cancer patients [23]. Higher
LDH level was related with shorter survival in various types
of cancer. In patients with non-small cell lung cancer
(N = 2531), normal baseline serum LDH levels were signifi-
cantly associated with better survival [5]. Similar reports were
seen in colorectal cancer [2], nasopharyngeal carcinoma [3, 4],
breast cancer [8, 9], prostate cancer [10], germ cell cancer [11,
12], and melanoma [13, 14].
Although LDH has five isoforms with different distribu-
tions, total serum LDH assessment being a routine part of
clinical work is convenient and cheap. Furthermore, total se-
rum LDH successfully predicted survival in previous studies
[2, 10, 11, 16], without the necessity to detect LDH isoforms
separately [8].
Our study enrolled patients with serum level of LDH
>1000 IU/L only. However, several studies had analyzed the
cut off value of serum LDH level which could be determined
as a prognostic factor, ranging from 220 IU/L in metastatic
renal cell carcinoma to 470 IU/L in metastatic pancreatic can-
cer [24, 25]. The cut off value in the present article was much
higher for we aimed to study the overall survival in patients
with advanced cancer and heavy tumor burden, and identified
patients with LDH greater than 1000 IU/L as patients in ad-
vanced stage according to previous studies. Brown et al.
conducted a multivariate analysis from 233 patients with met-
astatic breast cancer, and LDH was statistically significant
with increased risk of death. The risk of death was increased
almost 1.6-fold in patients with LDH levels >2 × ULN com-
pared those with levels <1 × ULN, and 4.5-fold in patients
with LDH levels >2 × ULN [8], suggesting that the higher the
LDH level, the higher the risk of death. Furthermore, in Suh
SY’ report, serum LDH levels increased in the terminal phase
and rose significantly to 630.40 ± 417.32 IU/L (213–1047 IU/
L) at 1 week before death [15], thus, LDH greater than
1000 U/L was a strong marker of terminal stage.
Additionally, Pui CH divided 330 childrenwith acute lympho-
blastic leukemia into three groups defined by LDH levels:
<300, 300 to 1000, and >1000 U/L. Patients with the highest
LDH levels (>1000 U/L) were most likely to fail treatment
and had the shortest time to failure [26]. Taken together, we
established 1000 IU/L as the cut off value of LDH.
This study had several limitations. The enrolled patients
were restricted to one local hospital, and the sample was rel-
atively small to justify the effect of multiple clinical features
on survival. The prognostic value of LDH level should be
evaluated in a larger, multicenter setting. Our study, however,
was of importance for its prediction of remaining life expec-
tancy for patients with serum LDH level greater than
4 × ULN. And decrease in LDH level was significantly related
to survival adjusted with other clinical variables. The prog-
nostic value of LDH level should be evaluated in a larger,
multicenter design.
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